Publications
Publications
Show Results For
- All HBS Web
(637)
- Faculty Publications (246)
- June 1997 (Revised October 2001)
- Case
Elliot Lebowitz
By: Paul A. Gompers and Alexander Tsai
Elliot Lebowitz, president and CEO of BioTransplant, must decide on a strategy for this young biotechnology start-up. Among the issues to be resolved are focus of research and search for strategic alliance partners. View Details
- June 1997 (Revised March 2001)
- Case
Genset Initial Public Offering (A)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research. View Details
- June 1997 (Revised September 1997)
- Case
Genset Initial Public Offering (B)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Supplements the (A) case. View Details
- March 1997
- Case
BioTransplant, Inc.: Initial Public Offering, January 1996
By: Paul A. Gompers and Alexander Tsai
Examines the decision to go public. BioTransplant is an early stage biotechnology company that must decide how to finance its research and development. The pros and cons of public offerings are analyzed versus alternative financing sources. View Details
- 1997
- Chapter
Patent Scope and Emerging Industries: Biotechnology, Software, and Beyond
By: Josh Lerner and Robert P. Merges
- August 1996 (Revised May 1997)
- Case
Delta & Pine Land: Measuring the Value of Transgenic Cotton
By: Ray A. Goldberg and Charlotte A. Tasker
Discusses the joint venture between two companies with different capabilities: 1) technology provider and 2) transportation agent. Discusses how to capture value from joint venture and biotechnology: 1) who are winners and who are losers; 2) how much value can/should... View Details
- January 1996
- Case
Biogen, Inc.: rBeta Interferon Manufacturing Process Development
Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing... View Details
- November 1995 (Revised February 1996)
- Case
Monsanto Company: The Coming of Age of Bio-Technology
By: Ray A. Goldberg and Thomas N. Urban Jr
Monsanto has one product, Roundup, accounting for 30% of company net income and is going off patent. How should the company position itself and its products in the future? View Details
- November 1995 (Revised March 1996)
- Case
Ares-Serono (Abridged)
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Keywords: Biotechnology Industry
- September 1995
- Case
Ares-Serono
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Biotechnology Industry; Biotechnology Industry; Switzerland; Europe
- April 1995 (Revised April 1999)
- Teaching Note
Aberlyn Capital Management TN
By: Josh Lerner
Teaching Note for (9-294-083). View Details
- October 1994 (Revised November 1994)
- Case
DNA Plant Technology Corporation (DNAP)
By: Ray A. Goldberg and Quintus Travis
Keywords: Biotechnology Industry
- January 1994 (Revised November 1997)
- Case
Aberlyn Capital Management: July 1993
By: Josh Lerner and Peter Tufano
Aberlyn Capital Management, a venture leasing firm specializing in providing capital to biotechnology firms, proposes to introduce a new product. Aberlyn will base a lease on an intangible product: the patent of a biotechnology firm. This poses a series of short and... View Details
- September 1993 (Revised February 1994)
- Case
Calgene, Inc.: Pioneering Agricultural Biotechnology
By: Ray A. Goldberg
- April 1993 (Revised November 1994)
- Case
Chiron Corp.
Pablo Valenzuela, vice president of R&D at Chiron Corp., faces several choices for how to allocate scarce resources across several promising projects. These choices will determine Chiron's position in several emerging biotechnology and diagnostic markets, including... View Details
- April 1993 (Revised October 1995)
- Case
ALZA and Bio-Electro Systems (A): Technological and Financial Innovation
By: Josh Lerner and Peter Tufano
To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details
- December 1992 (Revised September 1996)
- Case
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details
- October 1992 (Revised November 1997)
- Case
ImmuLogic Pharmaceutical Corporation (A): March 1991
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details